Status:
COMPLETED
Argatroban for Preventing Occlusion and Restenosis After Intracranial and Extracranial Artery Stenting
Lead Sponsor:
Jinling Hospital, China
Conditions:
CVD
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
Argatroban is a selective thrombin inhibitor, and previous study had suggested that argatroban use post PCI could potentially prevent reocclusion. But there has no study on large sample of argatroban ...
Detailed Description
The risk of restenosis post intracranial and extracranial artery stenting is 20-40%, therefore, in the past, aspirin and clopidogrel were performed as anticoagulant therapy post stenting.But this trea...
Eligibility Criteria
Inclusion
- For extracranial artery lesion, stenting was considered for symptomatic stenosis≥50% or asymptomatic stenosis≥70%; according to intracranial artery lesion, stenting was considered for symptomatic stenosis≥70% in invalid patients after intensive medical therapy.
- Successfully had intracranial or extracranial artery stenting
Exclusion
- Evidence of hemorrhagic brain infarction, intracranial and extracranial hematoma, or intraventricular hemorrhage, or Gastrointestinal ulcers in 3 months
- Hypersensitivity to contrast agent
- Malignant hypertension
- Difficult to perform the intracranial and extracranial artery stenting
- Severe hepatic or cardiac disorders, infectious disorders, dehydration, etc.
- Serum creatinine \>1.5 mg/dL
- Hypersensitivity to test drugs
- Difficult to hand follow-up visit
Key Trial Info
Start Date :
August 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2014
Estimated Enrollment :
114 Patients enrolled
Trial Details
Trial ID
NCT01163604
Start Date
August 1 2010
End Date
August 1 2014
Last Update
November 23 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Neurology, Jinling Hospital, Nanjing University School of Medicine
Nanjing, Jiangsu, China, 210002